Skip to main content
. 2019 May 26;12(8):1015–1025. doi: 10.1016/j.tranon.2019.05.003

Figure 2.

Figure 2

Suppressing the SRC pathway enhances the antitumor activity of JAKi in several human ovarian cancer cell lines. OVCAR8 (A), MDAH2774 (B), OVCAR 3 cells (C), CaOV3 cells (D), and primary ovarian cancer cells (E) were treated with JAKi or SRCi (saracatinib) either alone or in combination. Cell viability was determined 72 hours later. (F) Synergistic interaction between JAKi and SRCi on the viability of various ovarian cancer cells.